| |
Deliver high performance and continuity for your next obesity trial. IQVIA’s digital ecosystem drives data accuracy, deeper insights and more proactive decision-making. Accelerate your obesity clinical research success—download the case study!
|
|
|
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now.
|
|
| By Kevin Dunleavy Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being laid off, according to a Massachusetts Worker Adjustment and Retraining Notification. |
|
|
|
By Nick Paul Taylor AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. |
By Andrea Park,Nick Paul Taylor,Zoey Becker The top 10 meds were responsible for about a third of all pharmaceutical advertising spending in 2024; MediaRadar reported more than $10.1 billion spent marketing all prescription drugs last year, a year-over-year increase of about 2%. |
By Fraiser Kansteiner After taking aim at the United States’ vaccine safety reporting system earlier this year, Robert F. Kennedy Jr. has added a federal vaccine injury compensation program to his list of immunization bugbears. And this time around, the HHS Secretary says he already has a team working on a potential overhaul. |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
By Gabrielle Masson Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the investor has failed to meet its monetary commitments and warning of immediate consequences for its biotech portfolio. |
By Zoey Becker The former boy band star was first treated for Type 2 diabetes before being diagnosed with Type 1.5 diabetes, also known as latent autoimmune diabetes in adults, and effectively reaping the benefits of Dexcom's G7 continuous glucose monitor. |
By Angus Liu The Orphan Cures Act has been added back into the Senate version of President Donald Trump's “big, beautiful bill” after being left out in the chamber’s first rendition. |
By James Waldron Whether it’s drug developers being pressured to wind down or investors accused of trying to “strip mine” a biopharma, shareholder meetings are increasingly becoming verbal battlegrounds for beleaguered biotechs. |
By Fraiser Kansteiner As trade pressures and geopolitical uncertainties mount, it’s imperative that the European Union swiftly strengthen and adopt new policies that provide “targeted support for sustainable and resilient manufacturing,” Michal Nitka, chief of Teva’s Europe generics and global over-the-counter businesses, said via email. |
By James Waldron Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian biotech Unnatural Products to hunt down “undruggable” targets. |
By Fraiser Kansteiner Hikma plans to throw down $1 billion by 2030 to expand its manufacturing and R&D firepower in the U.S., where the company has been in operation since 1991. The investment plan plays into the Trump administration’s touted aim to increase production of drugs for U.S. patients on U.S. soil, with Hikma branding the initiative “America Leans on Hikma: Quality Medicines Manufactured in the USA.” |
By Darren Incorvaia Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. The company is paying 5 million Swiss francs ($6.3 million) upfront for a preclinical antibiotic program from BioVersys on which the two companies will work to turn into clinical candidates. |
By Conor Hale Medtronic said it received 33 reports of serious injuries related to the device. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "Podnosis," we explore how mental healthcare can evolve into a more connected, whole-person model. |
|
|---|
|
|
|
Now Available On-Demand Legacy GxP systems are holding life sciences back. Learn how to modernize your data infrastructure for better compliance, scalability, and integrity. Explore cloud, AI, and automation strategies in this expert session. Register now to future-proof your records management.
|
|
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Whitepaper Learn how to transform your Patient Support Programs into measurable patient-centric initiatives that inform strategic decision making. Sponsored by Herspiegel Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Learn how clinical terminology helps life sciences teams streamline cohorting, reduce bias, and accelerate evidence generation. Sponsored by: IMO Health |
| |
|
